Ann: Atomo receives TGA approval for COVID19 antibody test, page-136

@bariscan90
thanks for posting with updates - slight problem at my end.

I went through your chart + my notes from the PDI reports...how exactly are you rating them in terms of order?

The sample sizes vs claims vs results are not all comparable equally - even from PDI's own statements.

In some cases PDI didn't have enough IFU detail or specificity detail to be sure if their sample size/timeline age was sufficiently comparable or not. So, I am unsure how you are ending up rating the Best to Worst order column.

I agree some of the them are obviously 'worse' based on PDI's results VS claims. I was wondering if its better to re-group them into sections like 'Eual/Close to Claims' VS 'Below Claims' VS 'Significantly Below Claims'...something like this...+ to note the specificity/sensitivity results found VS claimed...for better clarity of better/ok/worse..

(These are semantics of course..in the end, it matters only what AT1 manages to sell in AU...but it sure is fun playing with spreadsheets...)